Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.

Literature DB >> 10681360

Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.

C A Stoddart¹, M E Moreno, V D Linquist-Stepps, C Bare, M R Bogan, A Gobbi, R W Buckheit, J Bedard, R F Rando, J M McCune.

Abstract

Oral administration of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652), a nucleoside analog structurally similar to lamivudine (3TC), caused dose-dependent inhibition of viral replication in SCID-hu Thy/Liv mice infected with human immunodeficiency virus type 1 NL4-3 and with an NL4-3 clone containing the M184V mutation in reverse transcriptase that confers resistance to 3TC. These experiments demonstrate the utility of this mouse model for evaluating drug resistance and for performing direct comparisons between antiviral compounds in vivo.

Entities: Chemical Disease Mutation Species

Mesh：

Substances：

Year: 2000 PMID： 10681360 PMCID： PMC89768 DOI： 10.1128/AAC.44.3.783-786.2000

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

29 in total

1. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.

Authors: J M de Muys; H Gourdeau; N Nguyen-Ba; D L Taylor; P S Ahmed; T Mansour; C Locas; N Richard; M A Wainberg; R F Rando
Journal: Antimicrob Agents Chemother Date: 1999-08 Impact factor: 5.191

2. Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro.

Authors: T S Mansour; H Jin; W Wang; E U Hooker; C Ashman; N Cammack; H Salomon; A R Belmonte; M A Wainberg
Journal: J Med Chem Date: 1995-01-06 Impact factor: 7.446

3. Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse.

Authors: H Kaneshima; L Su; M L Bonyhadi; R I Connor; D D Ho; J M McCune
Journal: J Virol Date: 1994-12 Impact factor: 5.103

4. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors: M Tisdale; S D Kemp; N R Parry; B A Larder
Journal: Proc Natl Acad Sci U S A Date: 1993-06-15 Impact factor: 11.205

5. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.

Authors: M A Wainberg; H Salomon; Z Gu; J S Montaner; T P Cooley; R McCaffrey; J Ruedy; H M Hirst; N Cammack; J Cameron
Journal: AIDS Date: 1995-04 Impact factor: 4.177

6. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry.

Authors: R Datema; L Rabin; M Hincenbergs; M B Moreno; S Warren; V Linquist; B Rosenwirth; J Seifert; J M McCune
Journal: Antimicrob Agents Chemother Date: 1996-03 Impact factor: 5.191

7. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.

Authors: C A Boucher; N Cammack; P Schipper; R Schuurman; P Rouse; M A Wainberg; J M Cameron
Journal: Antimicrob Agents Chemother Date: 1993-10 Impact factor: 5.191

8. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.

Authors: M F Kavlick; T Shirasaka; E Kojima; J M Pluda; F Hui; R Yarchoan; H Mitsuya
Journal: Antiviral Res Date: 1995-10 Impact factor: 5.970

9. HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo.

Authors: L Su; H Kaneshima; M Bonyhadi; S Salimi; D Kraft; L Rabin; J M McCune
Journal: Immunity Date: 1995-01 Impact factor: 31.745

10. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

Authors: R Schuurman; M Nijhuis; R van Leeuwen; P Schipper; D de Jong; P Collis; S A Danner; J Mulder; C Loveday; C Christopherson
Journal: J Infect Dis Date: 1995-06 Impact factor: 5.226

11 in total

1. Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice.

Authors: Cheryl A Stoddart; Geneviève Nault; Sofiya A Galkina; Nathalie Bousquet-Gagnon; Dominique Bridon; Omar Quraishi
Journal: Antimicrob Agents Chemother Date: 2012-01-17 Impact factor: 5.191

2. Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Authors: G M Bahr; E C Darcissac; N Castéran; C Amiel; C Cocude; M J Truong; J Dewulf; A Capron; Y Mouton
Journal: J Virol Date: 2001-08 Impact factor: 5.103

3. Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque.

Authors: Cheryl A Stoddart; Sofiya A Galkina; Pheroze Joshi; Galina Kosikova; Mary E Moreno; Jose M Rivera; Barbara Sloan; Aaron B Reeve; Stefan G Sarafianos; Michael Murphey-Corb; Michael A Parniak
Journal: Antimicrob Agents Chemother Date: 2015-05-04 Impact factor: 5.191

4. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors: J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal: Proc Natl Acad Sci U S A Date: 2001-10-16 Impact factor: 11.205

5. Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.

Authors: Cheryl A Stoddart; Sofiya A Galkina; Pheroze Joshi; Galina Kosikova; Brian R Long; Ekaterina Maidji; Mary E Moreno; Jose M Rivera; Ukina R Sanford; Barbara Sloan; Witold Cieplak; Terri Wrin; Po-Ying Chan-Hui
Journal: Virology Date: 2014-06-25 Impact factor: 3.616

6. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice.

Authors: Cheryl A Stoddart; Geneviève Nault; Sofiya A Galkina; Karen Thibaudeau; Peter Bakis; Nathalie Bousquet-Gagnon; Martin Robitaille; Maryanne Bellomo; Véronique Paradis; Patricia Liscourt; Alexandra Lobach; Marie-Eve Rivard; Roger G Ptak; Marie K Mankowski; Dominique Bridon; Omar Quraishi
Journal: J Biol Chem Date: 2008-09-22 Impact factor: 5.157

7. Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection.

Authors: Magnus Joakim Hansson; Steven James Moss; Michael Bobardt; Udayan Chatterji; Nigel Coates; Jose A Garcia-Rivera; Eskil Elmér; Steve Kendrew; Pieter Leyssen; Johan Neyts; Mohammad Nur-E-Alam; Tony Warneck; Barrie Wilkinson; Philippe Gallay; Matthew Alan Gregory
Journal: Chem Biol Date: 2015-01-22